1887

Chapter 4 : The Role of Complement in Antibody Therapy for Infectious Diseases

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in
Zoomout

The Role of Complement in Antibody Therapy for Infectious Diseases, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555817411/9781555817350_Chap04-1.gif /docserver/preview/fulltext/10.1128/9781555817411/9781555817350_Chap04-2.gif

Abstract:

The complement system is an integral and evolutionarily ancient component of the innate immune system, serving as the first line of defense against common pathogens ( Fig. 1 ) ( ). The prime functions of complement in innate host defense are accomplished through three effector pathways. These include lysis, inflammation, and opsonization ( Fig. 2 ). The latter is central to microbial recognition and clearance by phagocytic cells. Complement further cooperates with Toll-like receptors in response to microbial structure and infection, in which immune responses are determined through both synergistic and antagonistic manners ( ). Complement is also a functional bridge between innate and adaptive immunity, orchestrating an integrated host defense response to pathogenic challenges. For instance, complement can modulate adaptive immunity by providing signals that reinforce humoral responses to antigens by priming and regulating T cells and lowering the B-cell activation threshold ( ). It is also an important integral point for cross talk with other biological cascades to ensure homeostasis is maintained. One example is the interplay between the complement and coagulation cascades, whereby the complement system can amplify coagulation by enhancing local clotting and, as a result, preventing microbial spread through the systemic circulation. Likewise, the activated clotting factor XII can activate the classical complement pathway and thrombin can directly cleave the third and fifth complement components (C3 and C5, respectively) ( ).

Citation: Wibroe P, Helvig S, Moein Moghimi S. 2015. The Role of Complement in Antibody Therapy for Infectious Diseases, p 63-74. In Crowe J, Boraschi D, Rappuoli R (ed), Antibodies for Infectious Diseases. ASM Press, Washington, DC. doi: 10.1128/microbiolspec.AID-0015-2014
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Image of Figure 1
Figure 1

Schematic representation of complement activation by pathogens. The diagram shows the role of surface-bound antibodies and other complement-sensing molecules in complement triggering. Serum IgA is monomeric, but IgA in secretions is dimeric. IgM is pentameric. P, properdin; AP, alternative pathway.

Citation: Wibroe P, Helvig S, Moein Moghimi S. 2015. The Role of Complement in Antibody Therapy for Infectious Diseases, p 63-74. In Crowe J, Boraschi D, Rappuoli R (ed), Antibodies for Infectious Diseases. ASM Press, Washington, DC. doi: 10.1128/microbiolspec.AID-0015-2014
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 2
Figure 2

Antibody-mediated pathogen attack and elimination mechanisms.

Citation: Wibroe P, Helvig S, Moein Moghimi S. 2015. The Role of Complement in Antibody Therapy for Infectious Diseases, p 63-74. In Crowe J, Boraschi D, Rappuoli R (ed), Antibodies for Infectious Diseases. ASM Press, Washington, DC. doi: 10.1128/microbiolspec.AID-0015-2014
Permissions and Reprints Request Permissions
Download as Powerpoint

References

/content/book/10.1128/9781555817411.chap4
1. Ricklin D,, Hajishengallis G,, Yang K,, Lambris JD . 2010. Complement: a key system for immune surveillance and homeostasis. Nat Immunol 11 : 785 797.[PubMed] [CrossRef]
2. Carroll MC . 2004. The complement system in regulation of adaptive immunity. Nat Immunol 5 : 981 986.[PubMed]
3. Mastellos D,, Germenis AE,, Lambris JD . 2005. Complement: an inflammatory pathway fulfilling multiple roles at the interface of innate immunity and development. Curr Drug Targets Inflamm Allergy 4 : 125 127.[PubMed]
4. Markiewski MM,, Nilsson B,, Nilsson-Ekdahl K,, Mollnes TE,, Lambris JD . 2007. Complement and coagulation: strangers or partners in crime? Trends Immunol 28 : 184 192.[PubMed] [CrossRef]
5. Rittirsch D,, Flierl MA,, Ward PA . 2008. Harmful molecular mechanisms in sepsis. Nat Rev Immunol 8 : 776 787.[PubMed] [CrossRef]
6. Zipfel PF,, Skerka C . 2009. Complement regulators and inhibitory proteins. Nat Rev Immunol 9 : 729 740.[PubMed] [CrossRef]
7. ter Meulen J . 2011. Monoclonal antibodies in infectious diseases: clinical pipeline in 2011. Infect Dis Clin N Am 25 : 789 802.[PubMed] [CrossRef]
8. Saylor C,, Dadachova E,, Casadevall A . 2009. Monoclonal antibody-based therapies for microbial diseases. Vaccine 27( Suppl 6) : G38 G46.[PubMed] [CrossRef]
9. Krilov LR . 2011. Respiratory syncytial virus disease: update on treatment and prevention. Expert Rev Anti Infect Ther 9 : 27 32.[PubMed] [CrossRef]
10. Martínez I,, Melero JA . 1998. Enhanced neutralization of human respiratory syncytial virus by mixtures of monoclonal antibodies to the attachment (G) glycoprotein. J Gen Virol 79 : 2215 2220.[PubMed]
11. Moghimi SM,, Hamad I . 2008. Liposome-mediated triggering of complement cascade. J Liposome Res 18 : 195 209.[PubMed] [CrossRef]
12. Murphy K,, Travers P,, Walport M . 2008. Janeway’s Immunobiology, 7th ed. Garland Science, New York, NY.
13. Favoreel HW,, Van de Walle GR,, Nauwynck HJ,, Pensaert MB . 2003. Virus complement evasion strategies. J Gen Virol 84 : 1 15.[PubMed]
14. Ehrnthaller C,, Ignatius A,, Gebhard F,, Huber-Lang M . 2011. New insights of an old defense system: structure, function, and clinical relevance of the complement system. Mol Med 17 : 317 329.[PubMed] [CrossRef]
15. Sellborn A,, Andersson M,, Hedlund J,, Andersson J,, Berglin M,, Elwing H . 2005. Immune complement activation on polystyrene and silicon dioxide surfaces. Impact of reversible IgG adsorption. Mol Immunol 42 : 569 574.[PubMed] [CrossRef]
16. Pedersen MB,, Zhou XF,, Larsen EKU,, Sorensen US,, Kjems J,, Nygaard JV,, Nyengaard JR,, Meyer RL,, Boesen T,, Vorup-Jensen T . 2010. Curvature of synthetic and natural surfaces is an important target feature in classical pathway complement activation. J Immunol 184 : 1931 1945.[PubMed] [CrossRef]
17. Salfeld JG . 2007. Isotype selection in antibody engineering. Nat Biotechnol 25 : 1369 1372.[PubMed] [CrossRef]
18. Beenhouwer DO,, Yoo EM,, Lai C-W,, Rocha MA,, Morrison SL . 2007. Human immunoglobulin G2 (IgG2) and IgG4, but not IgG1 or IgG3, protect mice against Cryptococcus neoformans infection. Infect Immun 75 : 1424 1435.[PubMed] [CrossRef]
19. Berry JD,, Gaudet RG . 2011. Antibodies in infectious diseases: polyclonals, monoclonals and niche biotechnology. Nat Biotechnol 28 : 489 501.[PubMed]
20. Roos A,, Bouwman LH,, van Gijlswijk-Janssen DJ,, Faber-Krol MC,, Stahl GL,, Daha MR . 2001. Human IgA activates the complement system via the mannan-binding lectin pathway. J Immunol 167 : 2861 2868.[PubMed]
21. Janoff EN,, Fasching C,, Orenstein JM,, Rubins JB,, Opstad NL,, Dalmasso AP . 1999. Killing of Streptococcus pneumoniae by capsular polysaccharide-specific polymeric IgA, complement, and phagocytes. J Clin Investig 104 : 1139 1147.[PubMed] [CrossRef]
22. Hiemstra PS,, Gorter A,, Stuurman ME,, Van Es LA,, Daha MR . 1987. Activation of the alternative pathway of complement by human serum IgA. Eur J Immunol 17 : 321 326.[PubMed] [CrossRef]
23. Boackle RJ,, Nguyen QL,, Leite RS,, Yang X,, Vesely J . 2006. Complement-coated antibody-transfer (CCAT); serum IgA1 antibodies intercept and transport C4 and C3 fragments and preserve IgG1 deployment (PGD). Mol Immunol 43 : 236 245.[PubMed] [CrossRef]
24. van Egmond M,, van Spriel AB,, Vermeulen H,, Huls G,, van Garderen E,, van de Winkel JG . 2001. Enhancement of polymorphonuclear cell-mediated tumor cell killing on simultaneous engagement of fcgammaRI (CD64) and fcalphaRI (CD89). Cancer Res 61 : 4055 4060.[PubMed]
25. Jarvis GA,, Griffiss JM . 1991. Human IgA1 blockade of IgG-initiated lysis of Neisseria meningitidis is a function of antigen-binding fragment binding to the polysaccharide capsule. J Immunol 147 : 1962 1967.[PubMed]
26. Griffiss JM . 1975. Bactericidal activity of meningococcal antisera. Blocking by IgA of lytic antibody in human convalescent sera. J Immunol 114 : 1779 1784.[PubMed]
27. Weiner LM,, Surana R,, Wang S . 2010. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 10 : 317 327.[PubMed] [CrossRef]
28. Scott AM,, Wolchok JD,, Old LJ . 2012. Antibody therapy of cancer. Nat Rev Cancer 12 : 278 287.
29. Wright SD,, Silverstein SC . 1983. Receptors for C3b and C3bi promote phagocytosis but not the release of toxic oxygen from human phagocytes. J Exp Med 158 : 2016 2023.[PubMed]
30. Zhou X,, Hu W,, Qin X . 2008. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy. Oncologist 13 : 954 966.[PubMed]
31. Gelderman KA,, Tomlinson S,, Ross GD,, Gorter A . 2004. Complement function in mAb-mediated cancer immunotherapy. Trends Immunol 25 : 158 164.[PubMed] [CrossRef]
32. Vetvicka V,, Thornton BP,, Ross GD . 1996. Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells. J Clin Investig 98 : 50 61.[PubMed] [CrossRef]
33. Klos A,, Tenner AJ,, Johswich KO,, Ager RR,, Reis ES,, Kohl J . 2009. The role of the anaphylatoxins in health and disease. Mol Immunol 46 : 2753 2766.[PubMed] [CrossRef]
34. Shushakova N,, Skokowa J,, Schulman J,, Baumann U,, Zwirner J,, Schmidt RE,, Gessner JE . 2002. C5a anaphylatoxin is a major regulator of activating versus inhibitory FcgammaRs in immune complex-induced lung disease. J Clin Investig 110 : 1823 1830.[PubMed] [CrossRef]
35. Schmidt RE,, Gessner JE . 2005. Fc receptors and their interaction with complement in autoimmunity. Immunol Lett 100 : 56 67.[PubMed] [CrossRef]
36. Logtenberg T . 2007. Antibody cocktails: next-generation biopharmaceuticals with improved potency. Trends Biotechnol 25 : 390 394.[PubMed] [CrossRef]
37. Kennedy AD,, Beum PV,, Solga MD,, DiLillo DJ,, Lindorfer MA,, Hess CE,, Densmore JJ,, Williams ME,, Taylor RP . 2004. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol 172 : 3280 3288.[PubMed]
38. Kennedy AD,, Solga MD,, Schuman TA,, Chi AW,, Lindorfer MA,, Sutherland WM,, Foley PL,, Taylor RP . 2003. An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab. Blood 101 : 1071 1079.[PubMed] [CrossRef]
39. Klepfish A,, Gilles L,, Ioannis K,, Rachmilewitz EA,, Eliezer R,, Schattner A,, Ami S . 2009. Enhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma: complement/rituximab interactions and clinical results in refractory CLL. Ann N Y Acad Sci 1173 : 865 873.[PubMed] [CrossRef]
40. Wang S-Y,, Veeramani S,, Racila E,, Cagley J,, Fritzinger DC,, Vogel C-W,, St John W,, Weiner GJ . 2009. Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model. Blood 114 : 5322 5330.[PubMed] [CrossRef]
41. Wang S-Y,, Weiner G . 2008. Complement and cellular cytotoxicity in antibody therapy of cancer. Expert Opin Biol Ther 8 : 759 768.[PubMed] [CrossRef]
42. Wang SY,, Veeramani S,, Racila E,, Cagley J,, Fritzinger DC,, Vogel CW,, St John W,, Weiner GJ . 2009. Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model. Blood 114 : 5322 5330.[PubMed] [CrossRef]
43. Markiewski MM,, DeAngelis RA,, Benencia F,, Ricklin-Lichtsteiner SK,, Koutoulaki A,, Gerard C,, Coukos G,, Lambris JD . 2008. Modulation of the antitumor immune response by complement. Nat Immunol 9 : 1225 1235.[PubMed] [CrossRef]
44. Sarma JV,, Ward PA . 2011. The complement system. Cell Tissue Res 343 : 227 235.
45. Rooijakkers SH,, van Strijp JA . 2007. Bacterial complement evasion. Mol Immunol 44 : 23 32.[PubMed] [CrossRef]
46. Lambris JD,, Ricklin D,, Geisbrecht BV . 2008. Complement evasion by human pathogens. Nat Rev Microbiol 6 : 132 142.[PubMed] [CrossRef]
47. Szebeni J . 2004. The Complement System. Kluwer Academic Publisher, Boston, MA.
48. Peterson PK,, Verhoef J,, Sabath LD,, Quie PG . 1977. Effect of protein A on staphylococcal opsonization. Infect Immun 15 : 760 764.[PubMed]
49. Finlay BB,, McFadden G . 2006. Anti-immunology: evasion of the host immune system by bacterial and viral pathogens. Cell 124 : 767 782.[PubMed] [CrossRef]
50. Moghimi SM, . 2009. The innate immune responses, adjuvants and delivery systems, p 113 127. In Jorgensen L,, Nielsen HM (ed), Delivery Technologies for Biopharmaceuticals. Peptides, Proteins, Nucleic Acids and Vaccines. Wiley, Chichester, United Kingdom.
51. Li H,, Willingham SB,, Ting JP,, Re F . 2008. Cutting edge: inflammasome activation by alum and alum’s adjuvant effects are mediated by NLRP3. J Immunol 181 : 17 21.[PubMed]

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error